{"pmid":32415630,"title":"Is There a Role for ERAS Program Implementation to Restart Bariatric Surgery After the Peak of COVID-19 Pandemic?","text":["Is There a Role for ERAS Program Implementation to Restart Bariatric Surgery After the Peak of COVID-19 Pandemic?","Obes Surg","Fantola, Giovanni","Nagliati, Carlo","Foletto, Mirto","Balani, Alessandro","Moroni, Roberto","32415630"],"journal":"Obes Surg","authors":["Fantola, Giovanni","Nagliati, Carlo","Foletto, Mirto","Balani, Alessandro","Moroni, Roberto"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415630","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s11695-020-04676-0","topics":["Prevention"],"weight":1,"_version_":1666994545869455360,"score":9.490897,"similar":[{"pmid":32388706,"title":"The Impact of COVID-19 Pandemic on Obesity and Bariatric Surgery.","text":["The Impact of COVID-19 Pandemic on Obesity and Bariatric Surgery.","Obes Surg","Hussain, Abdulzahra","Mahawar, Kamal","El-Hasani, Shamsi","32388706"],"journal":"Obes Surg","authors":["Hussain, Abdulzahra","Mahawar, Kamal","El-Hasani, Shamsi"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388706","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s11695-020-04637-7","topics":["Prevention"],"weight":1,"_version_":1666428892618948608,"score":55.256493},{"pmid":32503846,"title":"Safely restarting GI endoscopy in the era of COVID-19.","text":["Safely restarting GI endoscopy in the era of COVID-19.","Gut","Hayee, Bu'Hussain","Thoufeeq, Mo","Rees, Colin J","Penman, Ian","East, James","32503846"],"journal":"Gut","authors":["Hayee, Bu'Hussain","Thoufeeq, Mo","Rees, Colin J","Penman, Ian","East, James"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503846","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/gutjnl-2020-321688","keywords":["endoscopy"],"topics":["Prevention"],"weight":1,"_version_":1668892488217133056,"score":53.55175},{"pmid":32291701,"pmcid":"PMC7155392","title":"Recommendations for Metabolic and Bariatric Surgery During the COVID-19 Pandemic from IFSO.","text":["Recommendations for Metabolic and Bariatric Surgery During the COVID-19 Pandemic from IFSO.","Obes Surg","Yang, Wah","Wang, Cunchuan","Shikora, Scott","Kow, Lilian","32291701"],"journal":"Obes Surg","authors":["Yang, Wah","Wang, Cunchuan","Shikora, Scott","Kow, Lilian"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291701","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s11695-020-04578-1","topics":["Prevention"],"weight":1,"_version_":1666138494432444417,"score":52.560833},{"pmid":32449169,"title":"How did we rapidly implement a convalescent plasma program?","text":["How did we rapidly implement a convalescent plasma program?","Since the beginning of the COVID-19 pandemic, the use of convalescent plasma as a possible treatment has been explored. Here we describe our experience as the first US organization creating a COVID-19 convalescent plasma program to support compassionate use through the single patient emergency IND, the National Expanded Access Program and multiple randomized control trials. Within weeks, we were able to distribute over 8000 products, scale up collections to over 4,000 units per week, meet hospital demand, as well as support randomized controlled trials to evaluate the efficacy of convalescent plasma treatment. This was through strategic planning, re-deployment of staff, and active engagement of hospital, community, and public health partners. Our partners helped with donor recruitment, testing, patient advocacy, and patient availability. The program will continue to evolve as we learn more about optimizing the product. Remaining issues to be resolved are antibody titers, dose, and at what stage of disease to transfuse.","Transfusion","Budhai, Alexandra","Wu, Annie A","Hall, Lucette","Strauss, Donna","Paradiso, Sarai","Alberigo, Jill","Hillyer, Christopher D","Jett, Betsy","Tobian, Aaron A R","Bloch, Evan M","Sachais, Bruce S","Shaz, Beth H","32449169"],"abstract":["Since the beginning of the COVID-19 pandemic, the use of convalescent plasma as a possible treatment has been explored. Here we describe our experience as the first US organization creating a COVID-19 convalescent plasma program to support compassionate use through the single patient emergency IND, the National Expanded Access Program and multiple randomized control trials. Within weeks, we were able to distribute over 8000 products, scale up collections to over 4,000 units per week, meet hospital demand, as well as support randomized controlled trials to evaluate the efficacy of convalescent plasma treatment. This was through strategic planning, re-deployment of staff, and active engagement of hospital, community, and public health partners. Our partners helped with donor recruitment, testing, patient advocacy, and patient availability. The program will continue to evolve as we learn more about optimizing the product. Remaining issues to be resolved are antibody titers, dose, and at what stage of disease to transfuse."],"journal":"Transfusion","authors":["Budhai, Alexandra","Wu, Annie A","Hall, Lucette","Strauss, Donna","Paradiso, Sarai","Alberigo, Jill","Hillyer, Christopher D","Jett, Betsy","Tobian, Aaron A R","Bloch, Evan M","Sachais, Bruce S","Shaz, Beth H"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32449169","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/trf.15910","locations":["US"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1667785214018977792,"score":48.60102},{"pmid":32374899,"title":"To test or not to test? An opportunity to restart dentistry sustainably in \"COVID-19 era\".","text":["To test or not to test? An opportunity to restart dentistry sustainably in \"COVID-19 era\".","COVID-19, which appeared to originate in China in December 2019, has spread worldwide pandemically. Recently, a letter regarding COVID-19 impact on dentistry has been published in this Journal (Prati et al. 2020). In Europe, Italy is the second most affected nation by COVID-19 infection and the first for number of deaths (WHO SR). In March 2020, the Italian Ministry of Health ordered the suspension of all non-urgent outpatient activities (including dentistry) in hospitals and clinics of the public health system, until the end of the lockdown (Press releases Italian Ministry of Health, 1).","Int Endod J","Giudice, Amerigo","Antonelli, Alessandro","Bennardo, Francesco","32374899"],"abstract":["COVID-19, which appeared to originate in China in December 2019, has spread worldwide pandemically. Recently, a letter regarding COVID-19 impact on dentistry has been published in this Journal (Prati et al. 2020). In Europe, Italy is the second most affected nation by COVID-19 infection and the first for number of deaths (WHO SR). In March 2020, the Italian Ministry of Health ordered the suspension of all non-urgent outpatient activities (including dentistry) in hospitals and clinics of the public health system, until the end of the lockdown (Press releases Italian Ministry of Health, 1)."],"journal":"Int Endod J","authors":["Giudice, Amerigo","Antonelli, Alessandro","Bennardo, Francesco"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374899","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/iej.13324","locations":["China","Italy"],"countries":["Italy","China"],"countries_codes":["ITA|Italy","CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666138496358678528,"score":48.59151}]}